Karyopharm Therapeutics (KPTI) Convertible Debt (2018 - 2024)
Karyopharm Therapeutics' (KPTI) quarterly Convertible Debt came in at $171.1 million in Q1 2024, little changed YoY from $170.3 million in Q2 2023, and little changed on a QoQ basis from $170.9 million in Q4 2023.
Karyopharm Therapeutics (KPTI) Convertible Debt (2018 - 2024) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 7 years of Convertible Debt data on file, last reported at $171.1 million in Q1 2024.
- Quarterly Convertible Debt changed 0.48% year-over-year to $171.1 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $171.1 million (changed 0.48% YoY) and the FY2023 annual result came in at $170.9 million, changed 0.48% from the prior year.
- Convertible Debt steadied at $171.1 million in Q1 2024, from $170.9 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $171.1 million in Q1 2024 to a low of $111.8 million in Q1 2020.
- A 5-year average of $156.9 million and a median of $169.5 million in 2022 frame the typical range for Convertible Debt.
- Annual changes were most pronounced in 2021 — Convertible Debt surged 50.94% — and 2022, when it gained 0.47%.
- Tracing KPTI's Convertible Debt over 5 years: stood at $117.9 million in 2020, then jumped by 43.56% to $169.3 million in 2021, then climbed by 0.48% to $170.1 million in 2022, then advanced by 0.48% to $170.9 million in 2023, then gained by 0.12% to $171.1 million in 2024.
- The last three Convertible Debt figures came in at $171.1 million (Q1 2024), $170.9 million (Q4 2023), and $170.7 million (Q3 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 171.13 Mn |
| Dec 31, 2023 | 170.92 Mn |
| Sep 30, 2023 | 170.70 Mn |
| Jun 30, 2023 | 170.50 Mn |
| Mar 31, 2023 | 170.31 Mn |
| Dec 31, 2022 | 170.11 Mn |
| Sep 30, 2022 | 169.89 Mn |
| Jun 30, 2022 | 169.69 Mn |
| Mar 31, 2022 | 169.49 Mn |
| Dec 31, 2021 | 169.29 Mn |
| Sep 30, 2021 | 169.09 Mn |
| Jun 30, 2021 | 168.90 Mn |
| Mar 31, 2021 | 168.70 Mn |
| Dec 31, 2020 | 117.93 Mn |
| Sep 30, 2020 | 115.80 Mn |
| Jun 30, 2020 | 113.78 Mn |
| Mar 31, 2020 | 111.77 Mn |
| Dec 31, 2019 | 109.86 Mn |
| Sep 30, 2019 | 107.96 Mn |
| Jun 30, 2019 | 106.16 Mn |